Furthermore, TP53 mutations are among the most prevalent concomitant mutations in patients with EGFR-mutated lung cancer, and mounting evidence shows that TP53 mutations can result in intrinsic resistance and poor prognosis [8,9,10]. This evidence concerns the gene EGFR and lung carcinoma.